Topics
Glioblastoma | Treatment | Clinical trials | Nivolumab
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Nivolumab
Sloan
AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N,
Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M,
Mehta MP.
NRG-BN002:
Phase I Study of Ipilimumab, Nivolumab, and the Combination in
Patients with Newly Diagnosed GBM.
Neuro
Oncol.
2024 Jun 14:noae058. doi:
10.1093/neuonc/noae058. PMID:
38874333. Interventional study˰ ˍ
Wen PY, Manzanera A, Duault C, Gonzalez-Kozlova E, Lopez L,
Grossman SA, Ye X, Fisher J, Lee I, Walbert T, Snyder J, Brem S,
Desai A, Bagley SJ, Kakani C, Strowd R, Tatter S, Laxton A, Lesser
G, Amankulor N, Lieberman F, Drappatz J, Mantica M, Triggs D,
Haymaker C, Wistuba II, Al-Atrash G, Mendoza Perez J, Futreal A,
Little LD, Islam MDH, Duose D, Jiang P, Reuben A, Lawler SE,
Pichavant M, Gentles A, Bendall S, Kong A, Camacho C, Del Valle D,
Kim-Schulze S, Gnjatic S, Sharon E, Nowicki MO, Peruzzi P, Lane D,
Aguilar-Cordova E, Aguilar LK, Nichols G, Dwyer J, Tak PP, Maecker
H, Barone F, Chiocca EA.
A
multi-institutional phase 1 clinical trial exploring upfront
multimodal standard of care and combined immunotherapies for newly
diagnosed glioblastoma.
Neuro
Oncol. 2025 Mar 22:noaf079. doi:
10.1093/neuonc/noaf079. PMID:
40120123. Interventional study˰
ˍ